Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
QuintilesIMS
Queensland Health
UBS
Citi
Harvard Business School

Generated: September 18, 2019

DrugPatentWatch Database Preview

Patent: 8,617,823

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,617,823
Title:Immunomodulating compositions and methods of use thereof
Abstract: The invention is directed to .beta.1-6 glucans, compositions, diagnostic kits, and devices comprising the same, and methods of use thereof in modulating immune response and treating, delaying progression of, reducing the incidence or severity of cancer, infection, inflammation, and autoimmune diseases. The .beta.1-6 glucans of certain embodiments of the invention are enriched for O-acetylated groups and/or conjugated to a solid support or linked to a targeting moiety. The .beta.1-6 glucans of certain embodiments of the invention recruit immunoglobulin G antibodies to mediate complement and neutrophil killing. The conjugated .beta.1-6 glucans of certain embodiments of the invention are targeted to cells to stimulate the immune response at the target location by activating complement-mediated lysis and recruitment of neutrophils.
Inventor(s): Rubin-Bejerano; Ifat (Belmont, MA), Fink; Gerald R. (Chesnut Hill, MA)
Assignee: Immunexcite, Inc. (Watertown, MA)
Application Number:12/990,066
Patent Claims:see list of patent claims

Details for Patent 8,617,823

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech RITUXAN rituximab VIAL 103705 001 1997-11-26   Try a Free Trial Immunexcite, Inc. (Watertown, MA) 2028-04-29 RX search
Medimmune SYNAGIS palivizumab VIAL 103770 001 1998-06-19   Try a Free Trial Immunexcite, Inc. (Watertown, MA) 2028-04-29 RX search
Medimmune SYNAGIS palivizumab VIAL 103770 002 1998-06-19   Try a Free Trial Immunexcite, Inc. (Watertown, MA) 2028-04-29 RX search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Try a Free Trial Immunexcite, Inc. (Watertown, MA) 2028-04-29 RX Orphan search
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 001 2001-05-07   Try a Free Trial Immunexcite, Inc. (Watertown, MA) 2028-04-29 RX Orphan search
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 002 2001-05-07   Try a Free Trial Immunexcite, Inc. (Watertown, MA) 2028-04-29 RX Orphan search
Genzyme LEMTRADA alemtuzumab INJECTABLE;INJECTION 103948 003 2001-05-07   Try a Free Trial Immunexcite, Inc. (Watertown, MA) 2028-04-29 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Cantor Fitzgerald
Teva
Queensland Health
Express Scripts
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.